Attention-deficit/hyperactivity disorder: state of research

Original KEYNOTE presentation and abstract by professor Tobias Banaschewski (Central Institute of Mental Health, Child and Adolescent Psychiatry and Psychotherapy, Mannheim, Germany) on attention-deficit/hyperactivity disorder (ADHD), held at the ESCAP 2013 Congress in Dublin, Monday 8th July 2013.

Image_from_the_presentation_by_tobias_banachewskiAbstract
Attention-Deficit/Hyperactivity Disorder (ADHD), characterized by a developmentally inappropriate, pervasive and persistent pattern of severe inattention, hyperactivity, and/or impulsivity with an early onset and associated with substantial functional impairment, is one of the most common mental disorders affecting around 5.3 % of children and adolescents.
ADHD symptomatology frequently co-exists with several other types of psychopathology, including oppositional defiant and conduct disorder, emotional lability, anxiety and depression, and persists into adulthood in a substantial number of cases. The disorder has a complex and probably heterogeneous pathogenesis, including multiple genetic and environmental risk factors of mostly small effect size which are acting together to cause a range of underlying neurobiological and neuropsychological alterations. According to various national and international guidelines, multimodal treatment components include psychoeducation, psychological interventions and various pharmacological treatment options. Interventions should be based on a comprehensive assessment and diagnosis, involving the integration of information from different sources, and interventions should be closely monitored for both efficacy and adverse effects.
The presentation summarized the current state of research with a special focus on recent research findings on underlying genetic and environmental risk factors, pathophysiological mechanisms, neurobiological and neuropsychological correlates, associated evidence based and alternative treatment options and proposed DSM-V changes.
Keywords: ADHD, pathogenesis, diagnosis, treatment.

Presentation
View the full presentation here (pdf file, 57 slides).

  • Tobias Banachewski

    Tobias Banaschewski MD PhD, is Professor of Child and Adolescent Psychiatry at the Medical Faculty Mannheim of the University of Heidelberg and Medical Director of the Department of Child and Adolescent Psychiatry of the Central Institute of Mental Health in Mannheim, Germany.

  • Dr Banaschewski studied psychology and medicine at the University of Marburg in Germany. He worked as Clinical Assistant in Adult Psychiatry in Marburg and as Clinical and Research Assistant in Child & Adolescent Psychiatry at the University of Göttingen. Dr. Banaschewski is member of the Executive Committee of the German Society of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, member of the Advisory Committee of the European Network for Hyperkinetic Disorders (EUNETHYDIS) and Co-Editor of the Journal of Child Psychology and Psychiatry (JCPP).

  • Tobias Banaschewski is an expert in the neurobiology, neuropsychology and psychopharmacology treatment of ADHD and associated child psychiatric disorders. 
    In 2003, Dr Banaschewski received the German research award for biological child and adolescent psychiatry for special scientific performance in clinical research, particularly for research into ADHD (Kramer-Pollnow-Preis).